Overview
Depression, often referred to as major depressive disorder (MDD), is a pervasive mental‑health condition that affects thoughts, emotions, physical health, and behavior. People with depression experience a persistent low mood that lasts for at least two weeks, accompanied by symptoms such as diminished pleasure in normally enjoyable activities, changes in appetite or weight, sleep disturbances, fatigue, feelings of worthlessness or excessive guilt, difficulty concentrating, and recurrent thoughts of death or suicide. While occasional sadness is a normal part of life, depression is distinguished by its intensity, duration, and the degree to which it interferes with daily functioning.The disorder is highly heterogeneous; it can present differently across age groups, genders, cultures, and comorbid medical conditions. For instance, adolescents may exhibit irritability rather than sadness, while older adults often report more somatic complaints like aches and pains. Biological factors—including neurotransmitter imbalances (serotonin, norepinephrine, dopamine), dysregulated hypothalamic‑pituitary‑adrenal (HPA) axis, and genetic predisposition—interact with psychosocial stressors such as trauma, loss, chronic illness, or socioeconomic hardship to precipitate depressive episodes. Effective management typically involves a combination of psychotherapy, pharmacotherapy, lifestyle modifications, and, when needed, more intensive interventions such as electroconvulsive therapy (ECT) or transcranial magnetic stimulation (TMS). If you or someone you know shows signs of depression, especially thoughts of self‑harm, seek professional help promptly.
History/Background
The concept of depression dates back to ancient civilizations; Hippocrates described “melancholia” as a disease of the black bile. In the 19th century, French psychiatrist Jean‑Étienne Dominique Esquirol distinguished melancholia from other mental illnesses, emphasizing its emotional and somatic features. The term “depression” entered psychiatric nomenclature in the early 20th century, largely through the work of Emil Kraepelin, who classified mood disorders alongside schizophrenia and dementia.A pivotal moment arrived in 1952 when John Cade discovered the antidepressant properties of monoamine oxidase inhibitors, leading to the monoamine hypothesis that still guides modern pharmacology. The 1960s and 1970s saw the development of tricyclic antidepressants and later selective serotonin reuptake inhibitors (SSRIs) in the 1980s, dramatically expanding treatment options. The Diagnostic and Statistical Manual of Mental Disorders (DSM‑III), published in 1980, provided standardized criteria for major depressive disorder, facilitating research and clinical consistency. In the 21st century, neuroimaging, genetics, and psychoneuroimmunology have deepened understanding of depression’s complex etiology, while global health initiatives have highlighted its burden—over 264 million people worldwide are affected, according to the World Health Organization (WHO).
